Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer.
Noori A M GumanRoos J van GeffenFrits I MulderThijs F van HaapsVahram HovsepjanMariette LabotsGeert A CirkelFilip Y F L de VosAlbert J Ten TijeLaurens V BeerepootVivianne C G Tjan-HeijnenHanneke W M van LaarhovenPaul HambergAnnelie J E VulinkMaartje LosAeilko H ZwindermanBart FerwerdaMartijn P J K LolkemaNeeltje SteeghsHarry R BüllerPieter W KamphuisenNick van EsPublished in: Journal of thrombosis and haemostasis : JTH (2021)
Performance of the PROTECHT or 5-SNP score was not superior to that of the Khorana score. The majority of cancer patients who developed VTE during 6-month follow-up were not identified by these scores. Future directions for studies on cancer-associated VTE prediction may include combined clinical-genetic scores.